Coherus Oncology Launches Stock Offering with 15% Greenshoe to Fund LOQTORZI Commercialization and Pipeline Development
Coherus Oncology announced an underwritten public offering of common stock with a 30-day option for underwriters to purchase up to 15% additional shares. The net proceeds will support LOQTORZI® commercialization, clinical development of mid-stage candidates Tagmokitug and Casdozokitug, and general corporate purposes.
1. Offering Structure
Coherus Oncology filed a proposed underwritten public offering of its common stock and granted underwriters a 30-day option to purchase up to 15% additional shares at the public offering price less discounts and commissions, subject to market conditions.
2. Intended Use of Proceeds
The company plans to use net proceeds to support ongoing commercialization of its approved PD-1 inhibitor LOQTORZI® (toripalimab-tpzi), advance clinical development of its mid-stage antibody candidates, and bolster working capital and other corporate needs.
3. Pipeline and Strategy
Coherus Oncology's pipeline includes LOQTORZI® for recurrent/metastatic nasopharyngeal carcinoma and combination trials, Tagmokitug in Phase 1b/2a for advanced solid tumors, and Casdozokitug in Phase 2 for first-line hepatocellular carcinoma, reflecting its focus on immuno-oncology growth.